OTCMKTS:NWBO Northwest Biotherapeutics Q2 2026 Earnings Results & Report $0.17 +0.00 (+0.96%) As of 11/11/2026 03:55 PM Eastern Northwest Biotherapeutics reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$0.01, while revenue was $810 thousand. Research:ProfileEarnings History Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeAfter Market Closes Northwest Biotherapeutics EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANorthwest Biotherapeutics Revenue ResultsActual Revenue$810 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNorthwest Biotherapeutics' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Northwest Biotherapeutics Q2 2026 Earnings FAQ Did Northwest Biotherapeutics beat earnings estimates for Q2 2026? Northwest Biotherapeutics (OTCMKTS:NWBO) reported earnings of -$0.01 per share for Q2 2026. The report was announced on Friday, August 14, 2026. What was Northwest Biotherapeutics' revenue for Q2 2026? Northwest Biotherapeutics reported revenue of $810 thousand for Q2 2026. When is Northwest Biotherapeutics' next earnings date? Northwest Biotherapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Northwest Biotherapeutics on the company's earnings history page. Northwest Biotherapeutics Earnings HeadlinesNorthwest Biotherapeutics Announces Expansion of Its Technical TeamOctober 26, 2026 | prnewswire.comNorthwest Biotherapeutics announces NHSBT collaboration to support DCVax-L production in the UKOctober 9, 2026 | msn.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionOctober 8, 2026 | prnewswire.comNorthwest Biotherapeutics highlights personalized cancer vaccine approach at NHS oncology conferenceOctober 6, 2026 | msn.comNorthwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual ...October 6, 2026 | finance.yahoo.comSee More Northwest Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email. Email Address About Northwest BiotherapeuticsNorthwest Biotherapeutics (OTCMKTS:NWBO) is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer. The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors. These candidates are not established treatments, and their development is subject to clinical and regulatory review. Northwest Biotherapeutics is headquartered in the United States and has manufacturing operations in the United Kingdom. Its work has included clinical research in multiple countries.View Northwest Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
